$76 Million Awarded to AstraZeneca from Apotex for Prilosec Generic
A U.S. federal judge awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing on patents for the heartburn drug, Prilosec® during 2003 to 2007. Dr. Gordon Rausser, Chairman and Co-founder of OnPoint Analytics, served as one of five expert witnesses for AstraZeneca.
Our experts and staff often publish in scholarly journals and provide continuing education to attorneys on economic and financial issues arising in litigation. Review our News entries for awards, events and commentary as well as information about recent verdicts and rulings.